A federal judge has declined to block Eli Lilly’s comparative advertising for its Zepbound weight-loss drug, handing the pharmaceutical giant a significant legal win against a challenge from rival Novo Nordisk. The ruling allows Lilly to continue running advertisements that draw direct comparisons between
